Introduction {#sec1}
============

Colorectal cancer (CRC) is a common form of cancer, with more than 1.5 million new patients diagnosed every year worldwide \[[@B1]\]. It is a complex chronic disease whose development is affected by genetic and environmental factors \[[@B2],[@B3]\]. CRC incidence rates differ between countries indicating that environmental factors may be associated with an increased cancer risk, although. A twin study indicated that the role of genetic factors is around 35% in CRC \[[@B4]\]. A previous genome-wide association study also indicated that single-nucleotide polymorphisms are important risk factors \[[@B5]\].

Glutathione S-transferases (*GSTs*) are a large family of enzymes that catalyze the conjugation of electrophiles to glutathione and the conversion of toxic compounds to hydrophilic metabolites \[[@B6],[@B7]\]. *GSTM1* maps to chromosome 1p13.3 contains 10 exons, while *GSTT1* maps to chromosome 22q11.23 and contains six exons. *GSTM1* present/null and *GSTT1* present/null polymorphisms have been reported in human \[[@B8]\]. The null genotypes are the most common polymorphisms in *GSTM1* and *GSTT1*, and have been proven to be associated with the loss of enzyme activity \[[@B12],[@B13]\].

To date, many studies have evaluated the association between *GSTM1* present/null and *GSTT1* present/null polymorphisms, and their combined effects with CRC risk \[[@B14],[@B108]\]. Additionally, 13 meta-analyses \[[@B115],[@B126],[@B127]\] have been conducted. However, a lot of studies have been published on these associations with CRC risk, therefore, an updated meta-analysis was performed to explore the association between *GSTM1* present/null, *GSTT1* present/null, and their combined effects on CRC risk in all populations.

Materials and methods {#sec2}
=====================

Search strategy {#sec2-1}
---------------

Meta-analyses of Observational Studies in Epidemiology (MOOSE) guidelines were used \[[@B128]\]. PubMed, Chinese Biomedical Medical databases (CBM), China National Knowledge Infrastructure (CNKI), and WanFang databases (up to March 15, 2020) were searched to identify eligible studies that analyzed the *GSTM1* present/null, *GSTT1* present/null, and their combined effects with CRC risk. The following keywords were used: (*GSTT1* OR glutathione S-transferase T1 OR *GSTM1* OR glutathione S-transferase M1) AND (polymorphism OR variant OR mutation) AND (colorectal OR rectal OR rectum OR colon). The search strategy was designed to be sensitive and broad. We first carefully reviewed the title and abstract of the search results, and then downloaded full articles to identify possible articles. These were evaluated in detail to identify relevant articles. The reference lists of identified articles and reviews was also examined as appropriate. The corresponding author may be contacted by e-mail if only the abstract was available online or the data was incomplete.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Inclusion criteria were as follows: (1) articles on the *GSTM1* present/null, *GSTT1* present/null, and their combined effects with CRC risk; (2) sufficient genotype data to calculate ORs and 95% CIs; and (3) case--control studies. Exclusion criteria were as follows: (1) no raw data; (2) no control; (3) review articles, case reports, editorials, or animal research; (4) duplicate and insufficient data.

Data extraction and quality score assessment {#sec2-3}
--------------------------------------------

Two investigators independently extracted data using Excel. Any disagreement was solved by iteration, discussion, and consensus. The following data were extracted from eligible studies: (1) first author's name, (2) publication year, (3) country, (4) source of controls (hospital-based and population-based case--control studies), (5) sample size, (6) genotyping method, and (6) genotype distribution of the *GSTM1, GSTT1*, and their combined effects in cases and controls. Different ethnicities included "Caucasians", "Asians", "Indians", and "Africans". If ethnicity was not stated or if the sample size could not be separated, the term "Mixed populations" was used. Two investigators independently assessed the quality of each individual study. The quality assessment criteria ([Table 1](#T1){ref-type="table"}) were obtained from two previous meta-analyses \[[@B129],[@B130]\]. The highest value is obtained from the quality assessment was nine; studies of quality scoring ≥ 6 were considered as high quality.

###### Scale for quality assessment

  Criteria                                                                                         Score
  ------------------------------------------------------------------------------------------------ -------
  Representativeness of cases                                                                      
  Selected from cancer registry or multiple cancer center sites                                    2
  Selected from oncology department or cancer institute                                            1
  Selected without clearly defined sampling frame or with extensive inclusion/exclusion criteria   0
  Source of controls                                                                               
  Population or community based                                                                    2
  Both population-based and hospital-based/healthy volunteers/blood donors                         1.5
  Hospital-based controls without colorectal cancer                                                1
  Cancer-free controls without total description                                                   0.5
  Not described                                                                                    0
  Ascertainment of colorectal cancer                                                               
  Histological or pathological confirmation                                                        2
  Diagnosis of colorectal cancer by patient medical record                                         1
  Not described                                                                                    0
  Sample size                                                                                      
  \>1000                                                                                           2
  200--1000                                                                                        1
  \<200                                                                                            0
  Quality control of genotyping methods                                                            
  Clearly described a different genotyping assay to confirm the data                               1
  Not described                                                                                    0

Statistical analysis {#sec2-4}
--------------------

We used crude odds ratios (ORs) and 95% confidence intervals (CIs) to estimate the association on the above issues. The genetic model of the individual *GSTM1* and *GSTT1* polymorphisms was null vs. present. Their combined effects used the following five genetic models: − − vs. + +, − − vs. + −, − − vs.− +, − − vs. (+ −) + (− +), and − − vs. (+ −) + (− +) + (+ +). − − referred to the *GSTM1* null/*GSTT1* null genotype, + − referred to the *GSTM1* present/*GSTT1* null genotype, − + referred to the *GSTM1* null/*GSTT1* present genotype, and + + referred to the *GSTM1* present/*GSTT1* present genotype. Heterogeneity among studies was tested using the *I*^2^ value \[[@B131]\]. A fixed-effects model (Mantel--Haenszel method) was used when *I*^2^ ≤ 50% \[[@B132]\]; otherwise, a random-effects model (DerSimonian and Laird method) was considered \[[@B133]\] if *I*^2^ \> 50%. However, these studies cannot be pooled into together when *I*^2^ value \> 75%. Subgroup analyses were performed by ethnicity, source of controls, tumor location, smoking history, gender, quality score, and tumor site. Then, a sensitivity analysis was carried out to assess the stability, a single study was excluded one at a time. Publication bias was tested by using Begg's funnel and Egger's test (significant publication bias was considered if *P* \< 0.05). A nonparametric "trim and fill" method was applied to accredit missing studies if publication bias was detected. Finally, a meta-regression analysis was applied to assess the heterogeneity source. All results were calculated using Stata version 9.0 (Stata Corporation, College Station, TX, U.S.A.).

Results {#sec3}
=======

Study characteristics {#sec3-1}
---------------------

A flowchart of study selection is shown in [Figure 1](#F1){ref-type="fig"}. Overall, 472 articles were identified by electronic database searching. Of these, 115 full-text articles were selected after carefully screening titles and abstracts. Fourteen articles were excluded because they were not case-control studies, while the data of fourteen articles \[[@B18],[@B25],[@B37],[@B43],[@B61],[@B65],[@B79],[@B84],[@B86],[@B92],[@B94],[@B95],[@B100],[@B110]\] overlapped with those of another nine articles \[[@B26],[@B41],[@B47],[@B48],[@B93],[@B105],[@B107],[@B108],[@B114]\]. Hence, a total of 87 articles were included in the present meta-analysis.

![Flow diagram for identifying and including studies in the current meta-analysis](bsr-40-bsr20201927-g1){#F1}

The main study characteristics are listed in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. Eighty-five publications involving eighty-six case--control studies \[[@B14],[@B19],[@B26],[@B38],[@B44],[@B62],[@B66],[@B80],[@B85],[@B87],[@B88],[@B90],[@B91],[@B93],[@B96],[@B101],[@B103],[@B108],[@B109],[@B111]\] were included on the *GSTM1* present/null polymorphism (24,931 cases and 36,537 controls; 44 studies on Caucasians, 31 on Asians, one on Africans, one on Indians, and nine on mixed populations) with CRC risk. Sixty-three articles of sixy-four case--control studies \[[@B15],[@B19],[@B21],[@B26],[@B27],[@B30],[@B31],[@B33],[@B34],[@B36],[@B38],[@B45],[@B47],[@B48],[@B54],[@B62],[@B67],[@B73],[@B74],[@B76],[@B80],[@B87],[@B93],[@B96],[@B102],[@B105],[@B109],[@B111]\] were eligible concerning the *GSTT1* present/null polymorphism (19,725 cases and 28,725 controls; 34 studies on Caucasians, 23 on Asians, one on Indians, one on Africans, and five on mixed populations) with CRC risk. Thirty-two publications of thirty-three case--control studies \[[@B15],[@B19],[@B22],[@B27],[@B31],[@B33],[@B38],[@B39],[@B41],[@B42],[@B45],[@B49],[@B52],[@B55],[@B63],[@B67],[@B68],[@B70],[@B76],[@B90],[@B96],[@B97],[@B99],[@B105],[@B109],[@B112]\] were included regarding their combined effects (8270 cases and 14,381 controls; 11 studies on Caucasians, 17 on Asians, one on Indians, one on Africans, and three on mixed populations) with CRC risk. Fifty-five studies had a quality score ≥ 6 and the remaining 31 had a quality score \< 6 regarding the *GSTM1* present/null polymorphism; 48 high-quality studies were examined and the remaining 16 were low-quality concerning the *GSTT1* present/null polymorphism; a total of 25 high-quality and eight low-quality studies were included on their combined effects with CRC risk.

###### The data between the *GSTM1* and *GSTT1* polymorphisms and colorectal cancer risk

  First author/Year                    Country        Ethnicity   SC   Sample size (case/ control)   Genotyping methods           *GSTM1* genotype distribution   *GSTT1* genotype distribution   Quality scores                                     
  ------------------------------------ -------------- ----------- ---- ----------------------------- ---------------------------- ------------------------------- ------------------------------- ---------------- ------ ------ ----- ------- ----- -----
  Stojkovic \[[@B111]\] 2019           Serbia         Caucasian   HB   509/399                       Multiplex PCR                249                             260                             204              195    145    364   91      308   6
  Rodrigues-Fleming \[[@B112]\] 2018   Brazil         Mixed       HB   232/738                       Multiplex PCR and PCR-RFLP   100                             132                             385              353    192    40    573     165   6.5
  Waś \[[@B113]\] 2018                 Poland         Caucasian   HB   279/233                       PCR                          151                             128                             133              100    220    59    189     44    6
  Klusek \[[@B114]\] 2018              Poland         Caucasian   HB   197/104                       TaqMan                       105                             92                              57               47     166    31    83      21    6
  Gorukmez \[[@B49]\] 2016             Turkey         Caucasian   HB   92/116                        Multiplex PCR                65                              27                              67               49     58     34    91      25    4
  Khabaz \[[@B32]\] 2016               Saudi Arabia   Caucasian   HB   83/35                         PCR                          14                              69                              12               23     NA     NA    NA      NA    3
  Zeng \[[@B99]\] 2016                 China          Asian       HB   108/215                       PCR                          38                              70                              110              105    48     60    117     98    6
  Djansugurova \[[@B34]\] 2015         Kazakhstan     Mixed       HB   249/245                       Site-specific PCR            124                             125                             158              87     171    78    164     81    4.5
  Cong \[[@B33]\] 2014                 China          Asian       PB   264/317                       Multiplex PCR                122                             142                             182              135    125    139   190     127   6
  Procopciuc \[[@B85]\] 2014           Romania        Caucasian   HB   150/162                       PCR-RFLP                     60                              90                              97               65     NA     NA    NA      NA    6
  Vogtmann \[[@B31]\] 2014             China          Asian       PB   340/673                       Real-time PCR                134                             201                             259              379    164    173   350     318   8
  Kassab \[[@B76]\] 2014               Tunisia        Caucasian   HB   147/128                       Multiplex PCR                43                              104                             41               87     90     57    65      63    6
  Saeed \[[@B14]\] 2013                Saudi Arabia   Caucasian   HB   100/79                        PCR                          98                              2                               79               0      NA     NA    NA      NA    5
  Chirila \[[@B15]\] 2013              Romania        Caucasian   HB   19/19                         Multiple PCR                 14                              5                               15               4      15     4     16      3     3
  Hezova \[[@B16]\] 2012               Czech          Caucasian   HB   197/218                       Duplex PCR                   97                              100                             117              101    157    40    179     39    6.5
  Rudolph \[[@B17]\] 2012              German         Caucasian   PB   1796/1806                     Multiplex PCR                822                             932                             844              923    1433   313   1459    308   6
  Huang \[[@B96]\] 2012                China          Asian       HB   130/100                       PCR                          71                              59                              58               42     63     67    52      48    6
  Darazy \[[@B20]\] 2011               Lebanese       Caucasian   HB   67/70                         PCR                          32                              25                              58               12     NA     NA    NA      NA    3.5
  Wang \[[@B23]\] 2011                 India          Indian      HB   302/291                       Multiplex PCR                202                             100                             215              76     245    57    247     44    6
  Koh \[[@B19]\] 2011                  China          Asian       PB   480/1167                      TaqMan                       246                             234                             641              526    294    186   691     476   8
  Cleary \[[@B21]\] 2010               Canada         Caucasian   PB   1174/1293                     Multiplex PCR                550                             616                             608              684    953    213   1,067   223   9
  Yang \[[@B24]\] 2010                 China          Asian       PB   322/1251                      Real-time PCR                133                             189                             521              730    158    164   639     612   8
  Nisa \[[@B78]\] 2010                 Japan          Asian       PB   685/778                       Multiplex PCR                328                             357                             356              422    347    338   435     343   8
  Zhang SS \[[@B50]\] 2010             China          Asian       PB   197/399                       Multiplex PCR                83                              114                             184              215    150    47    310     89    6
  Hlavata \[[@B22]\] 2010              Czech          Caucasian   HB   495/495                       PCR-RFLP                     228                             267                             254              241    392    103   395     100   6
  Csejtei \[[@B26]\] 2009              Hungary        Caucasian   HB   102/97                        PCR                          42                              60                              51               46     68     34    77      20    4
  Piao \[[@B77]\] 2009                 Korea          Asian       PB   1829/1699                     Real-time PCR                825                             1,004                           776              923    879    950   841     858   9
  Matakova \[[@B27]\] 2009             Slovak         Caucasian   PB   183/402                       PCR                          83                              100                             202              220    142    41    329     93    6
  Zupa \[[@B28]\] 2009                 Italy          Caucasian   HB   92/121                        PCR                          31                              61                              53               68     NA     NA    NA      NA    5
  Curtin \[[@B29]\] 2009               U.S.A.         Caucasian   PB   750/1201                      PCR                          310                             323                             465              545    NA     NA    NA      NA    8
  Epplein \[[@B30]\] 2009              U.S.A.         Mixed       PB   173/313                       TaqMan                       82                              91                              166              147    127    46    201     112   7
  Lin LM \[[@B93]\] 2008               China          Asian       HB   120/204                       Multiplex PCR                51                              69                              114              90     56     64    119     85    6
  Yang ZF \[[@B46]\] 2008              China          Asian       HB   84/112                        PCR                          24                              60                              61               51     NA     NA    NA      NA    5
  Cotterchio \[[@B88]\] 2008           Canada         Caucasian   PB   836/1249                      Multiplex PCR                395                             441                             588              661    679    157   1,029   219   8
  Kury \[[@B87]\] 2008                 France         Caucasian   PB   1023/1121                     TaqMan                       479                             544                             553              568    840    183   916     205   8
  Skjelbred \[[@B36]\] 2007            Norway         Caucasian   PB   108/299                       Multiplex PCR                53                              55                              148              151    93     15    262     37    6
  Yoshida \[[@B35]\] 2007              Japan          Asian       PB   66/121                        PCR                          30                              36                              59               62     NA     NA    NA      NA    3
  Xia \[[@B59]\] 2007                  China          Asian       HB   112/140                       PCR                          45                              67                              77               63     NA     NA    NA      NA    6
  Huang \[[@B105]\] 2007               China          Asian       HB   57/68                         PCR                          17                              40                              33               35     33     24    44      24    5
  Martínez \[[@B38]\] 2006             Spain          Caucasian   PB   144/329                       Multiplex PCR                55                              87                              180              149    68     74    253     76    6
  Probst-Hensch \[[@B39]\] 2006        China          Asian       PB   300/1169                      TaqMan                       168                             132                             643              525    200    100   693     475   9
  Little \[[@B40]\] 2006               U.K.           Caucasian   PB   241/383                       PCR                          110                             131                             162              221    192    49    318     65    7
  Fan \[[@B41]\] 2006                  China          Asian       PB   140/343                       PCR                          58                              80                              151              188    113    25    270     69    6
  Huang \[[@B42]\] 2006                U.S.A.         Caucasian   PB   315/547                       Multiplex PCR                135                             180                             258              289    241    74    385     162   6
  Huang \[[@B42]\] 2006                U.S.A.         African     PB   239/327                       Multiplex PCR                162                             77                              245              82     187    56    218     109   6
  Fu \[[@B98]\] 2006                   China          Asian       PB   315/439                       PCR                          86                              229                             117              321    141    174   187     251   7
  Luo \[[@B91]\] 2006                  China          Asian       HB   56/143                        PCR                          36                              20                              95               48     NA     NA    NA      NA    3
  Rajagopal \[[@B89]\] 2005            U.K.           Caucasian   HB   361/881                       PCR                          NA                              NA                              NA               NA     265    96    723     158   7
  Landi \[[@B44]\] 2005                Spain          Caucasian   HB   176/162                       PCR                          77                              99                              66               96     NA     NA    NA      NA    4
  Ateş \[[@B45]\] 2005                 Turkey         Caucasian   HB   181/204                       Real-Time PCR                83                              98                              116              88     118    63    151     53    6
  Yeh \[[@B47]\] 2005                  China          Asian       HB   727/736                       Multiplex PCR                325                             402                             326              410    331    396   376     360   7
  van der Logt \[[@B51]\] 2004         U.S.A.         Caucasian   PB   371/415                       PCR                          186                             184                             212              203    299    72    346     69    4
  Kiss \[[@B48]\] 2004                 Hungary        Caucasian   HB   500/500                       PCR                          209                             291                             258              242    369    131   392     108   6
  Chen \[[@B109]\] 2004                China          Asian       HB   125/339                       PCR                          56                              69                              151              188    102    23    270     69    7
  Smits \[[@B53]\] 2003                Multiple       Caucasian   PB   724/1743                      PCR                          381                             343                             821              922    NA     NA    NA      NA    7.5
  van der Hel \[[@B54]\] 2003          U.S.A.         Caucasian   PB   212/765                       PCR                          124                             88                              396              369    154    58    541     224   6
  Slattery \[[@B107]\] 2003            U.S.A.         Mixed       PB   801/1013                      PCR                          397                             404                             467              546    NA     NA    NA      NA    6
  Nascimento \[[@B55]\] 2003           Brazil         Mixed       HB   102/300                       Multiplex PCR                52                              50                              166              134    85     17    248     52    6
  Huang \[[@B90]\] 2003                China          Asian       HB   82/82                         Multiplex PCR                36                              46                              54               28     41     41    42      40    5
  Yang \[[@B101]\] 2003                China          Asian       HB   58/65                         PCR-RFLP                     18                              40                              36               29     NA     NA    NA      NA    3
  Zhang \[[@B102]\] 2003               China          Asian       HB   81/112                        Multiplex PCR                NA                              NA                              NA               NA     27     54    54      58    5
  Zhu \[[@B57]\] 2002                  China          Asian       HB   104/101                       Multiplex PCR                56                              48                              44               57     55     49    40      61    6
  Ye \[[@B58]\] 2002                   U.K.           Caucasian   HB   41/82                         Specific PCR                 21                              20                              49               33     39     2     73      9     5
  Tiemersma \[[@B60]\] 2002            U.S.A.         Mixed       PB   102/537                       PCR                          44                              58                              252              285    NA     NA    NA      NA    6
  Seow \[[@B56]\] 2002                 China          Asian       PB   213/1194                      TaqMan                       105                             108                             653              537    133    80    710     480   9
  Sachse \[[@B81]\] 2002               U.K.           Caucasian   PB   490/593                       PCR                          206                             284                             291              302    306    184   378     215   6
  Laso \[[@B82]\] 2002                 Spain          Caucasian   HB   247/296                       Multiplex PCR                114                             133                             138              158    116    131   263     33    6
  Sgambato \[[@B83]\] 2002             Italy          Caucasian   HB   44/100                        Duplex PCR                   12                              32                              47               53     NA     NA    NA      NA    3
  Slattery \[[@B108]\] 2002            U.S.A.         Mixed       PB   1577/1904                     PCR                          761                             816                             892              1012   NA     NA    NA      NA    9
  Butler \[[@B62]\] 2001               Australia      Caucasian   PB   219/200                       PCR                          97                              106                             92               108    123    67    160     40    4
  Saadat \[[@B63]\] 2001               Iran           Caucasian   HB   46/131                        PCR                          21                              25                              78               53     28     18    90      41    5
  Loktionov \[[@B64]\] 2001            U.K.           Caucasian   HB   206/355                       PCR                          73                              133                             147              208    166    40    301     54    6
  Zhang \[[@B103]\] 2001               China          Asian       HB   52/52                         Multiplex PCR                30                              22                              27               25     NA     NA    NA      NA    5
  Zhou \[[@B97]\] 2000                 China          Asian       HB   55/62                         PCR                          21                              34                              29               33     24     31    31      31    5
  Gawrońska-Szklarz \[[@B66]\] 1999    Poland         Caucasian   HB   70/145                        PCR                          24                              46                              73               72     NA     NA    NA      NA    6
  Yoshioka \[[@B67]\] 1999             Japan          Asian       HB   106/100                       PCR                          50                              56                              58               42     55     51    59      41    6
  Abdel-Rahman \[[@B68]\] 1999         Egypt          Caucasian   HB   66/55                         PCR                          26                              37                              15               30     37     22    30      21    4
  Zhang \[[@B80]\] 1999                Sweden         Caucasian   HB   94/109                        Multiplex PCR                50                              44                              54               55     44     50    87      22    6
  Welfare \[[@B69]\] 1999              U.K.           Caucasian   PB   196/178                       PCR                          94                              102                             88               90     157    39    148     30    6
  Gao \[[@B104]\] 1998                 China          Asian       HB   19/70                         PCR                          12                              7                               45               25     NA     NA    NA      NA    5
  Lee \[[@B71]\] 1998                  Singapore      Asian       HB   300/183                       NA                           172                             128                             94               89     NA     NA    NA      NA    4
  Gertig \[[@B70]\] 1998               U.S.A.         Mixed       PB   212/221                       PCR                          97                              114                             104              117    173    36    169     51    7
  Guo \[[@B72]\] 1996                  China          Asian       HB   19/23                         PCR                          12                              7                               17               6      NA     NA    NA      NA    5
  Katoh \[[@B73]\] 1996                Japan          Asian       HB   103/126                       Multiplex PCR                47                              56                              71               55     53     50    70      56    4
  Deakin \[[@B52]\] 1996               U.K.           Caucasian   HB   252/577                       PCR                          117                             135                             261              316    189    63    415     94    4
  Chenevix-Trench \[[@B74]\] 1995      Australia      Caucasian   HB   132/200                       NA                           68                              64                              99               101    79     15    125     23    2
  Zhong \[[@B75]\] 1993                U.K.           Caucasian   PB   196/225                       PCR                          86                              110                             131              94     NA     NA    NA      NA    4
  Strange \[[@B106]\] 1991             U.K.           Mixed       HB   19/502                        HSE                          5                               14                              249              253    NA     NA    NA      NA    5

Abbreviations: HB, hospital-based study; HSE, horizontal starch gel electrophoresis; PB, population-based study; SC, source of control.

###### The data between combined effects of *GSTM1* and *GSTT1* polymorphisms and colorectal cancer risk

  First author/Year                    Country   Ethnicity   SC   Sample size   \+ −   − +   − −   \+ +   \+ − or − +   \+ +, + −, or − +   Quality scores                                   
  ------------------------------------ --------- ----------- ---- ------------- ------ ----- ----- ------ ------------- ------------------- ---------------- ----- ----- ----- ------ ------ -----
  Rodrigues-Fleming \[[@B112]\] 2018   Brazil    Mixed       HB   232/738       19     82    97    270    14            83                  68               303   116   352   184    655    6.5
  Gorukmez \[[@B49]\] 2016             Turkey    Caucasian   HB   92/116        31     11    24    35     3             14                  34               56    55    46    89     102    4
  Zeng \[[@B99]\] 2016                 China     Asian       HB   108/215       25     64    35    71     35            34                  13               46    60    135   73     181    6
  Kassab \[[@B76]\] 2014               Tunisia   Caucasian   HB   147/128       NA     NA    NA    NA     45            26                  NA               NA    NA    NA    102    102    6
  Cong \[[@B33]\] 2014                 China     Asian       PB   264/317       22     54    23    44     119           83                  100              136   45    98    145    234    6
  Vogtmann \[[@B31]\] 2014             China     Asian       PB   332/633       NA     NA    NA    NA     106           169                 67               128   159   336   226    464    8
  Chirila \[[@B15]\] 2013              Romania   Caucasian   HB   19/19         NA     NA    NA    NA     2             3                   3                15    14    1     17     16     3
  Huang \[[@B96]\] 2012                China     Asian       HB   130/100       NA     NA    NA    NA     15            12                  46               42    NA    NA    115    88     6
  Wang \[[@B23]\] 2011                 India     Indian      HB   302/291       42     37    85    69     15            7                   160              178   127   106   287    284    6
  Koh \[[@B19]\] 2011                  China     Asian       PB   480/1167      NA     NA    NA    NA     163           421                 108              263   209   483   317    746    8
  Yang \[[@B24]\] 2010                 China     Asian       PB   322/1247      NA     NA    NA    NA     96            326                 65               234   161   687   226    921    8
  Nisa \[[@B78]\] 2010                 Japan     Asian       PB   685/778       NA     NA    NA    NA     183           189                 NA               NA    NA    NA    502    589    8
  Hlavata \[[@B22]\] 2010              Czech     Caucasian   HB   495/495       NA     NA    NA    NA     61            46                  186              200   248   249   434    449    6
  Piao \[[@B77]\] 2009                 Korea     Asian       PB   1829/1699     428    391   477   456    533           467                 391              385   905   847   1296   1232   9
  Matakova \[[@B27]\] 2009             Slovak    Caucasian   PB   183/422       20     35    83    162    19            58                  61               167   103   197   164    364    6
  Huang \[[@B105]\] 2007               China     Asian       HB   57/68         3      13    19    24     19            24                  14               20    22    37    36     57     5
  Martínez \[[@B38]\] 2006             Spain     Caucasian   PB   142/329       NA     NA    NA    NA     40            24                  21               128   81    177   102    305    6
  Probst-Hensch \[[@B39]\] 2006        China     Asian       PB   300/1168      NA     NA    NA    NA     45            222                 NA               NA    NA    NA    255    946    9
  Fan \[[@B41]\] 2006                  China     Asian       PB   138/339       5      33    60    152    20            36                  53               118   65    185   118    303    6
  Huang \[[@B42]\] 2006                U.S.A.    Caucasian   PB   315/547       36     79    142   206    38            83                  99               179   178   285   277    464    6
  Huang \[[@B42]\] 2006                U.S.A.    African     PB   239/327       37     82    58    55     19            27                  125              163   95    137   220    300    6
  Ateş \[[@B45]\] 2005                 Turkey    Caucasian   HB   180/204       36     34    71    69     27            19                  46               82    107   103   153    185    6
  Chen \[[@B109]\] 2004                China     Asian       HB   125/339       5      32    51    152    18            35                  51               119   56    184   107    303    7
  Nascimento \[[@B55]\] 2003           Brazil    Mixed       HB   102/300       NA     NA    NA    NA     9             24                  44               138   49    138   93     276    6
  Huang \[[@B90]\] 2003                China     Asian       HB   82/82         15     26    20    14     26            14                  21               28    35    40    56     68     5
  Zhu \[[@B57]\] 2002                  China     Asian       HB   104/101       35     37    31    36     28            11                  10               17    66    73    76     90     6
  Seow \[[@B56]\] 2002                 China     Asian       PB   213/1190      NA     NA    NA    NA     39            224                 NA               NA    NA    NA    174    966    9
  Saadat \[[@B63]\] 2001               Iran      Caucasian   HB   46/131        9      27    16    39     9             14                  12               51    25    66    37     117    5
  Zhou \[[@B97]\] 2000                 China     Asian       HB   55/62         14     14    17    16     17            17                  7                15    31    30    38     45     5
  Yoshioka \[[@B67]\] 1999             Japan     Asian       HB   106/100       20     22    25    23     31            19                  30               36    45    45    75     81     6
  Abdel-Rahman \[[@B68]\] 1999         Egypt     Caucasian   HB   56/49         10     4     18    17     12            17                  16               11    28    21    44     32     4
  Gertig \[[@B70]\] 1998               U.S.A.    Mixed       PB   208/220       NA     NA    NA    NA     24            23                  83               75    101   122   184    197    7
  Deakin \[[@B52]\] 1996               U.K.      Caucasian   HB   218/448       38     37    89    207    26            42                  65               162   127   244   192    406    4

Abbreviations: HB hospital-based studies; NA not available; PB population-based studies; SC, source of controls.

Meta-analysis results {#sec3-2}
---------------------

### *GSTM1* present/null polymorphisms {#sec3-2-1}

[Table 4](#T4){ref-type="table"} lists the summary ORs and 95% CIs on the *GSTM1* null genotype with CRC risk. The *GSTM1* null genotype was associated with an increased CRC risk (OR = 1.17, 95% CI: 1.10--1.23, *I*^2^ = 55.8%) in the overall population. In subgroup analyses by ethnicity, source of controls, and quality score, a significantly increased CRC risk was observed in Caucasians (OR = 1.14, 95% CI: 1.05--1.23, *I*^2^ = 56.7%, [Figure 2](#F2){ref-type="fig"}) and Asians (OR = 1.19, 95% CI: 1.08--1.32, *I*^2^ = 52.7%, [Figure 3](#F3){ref-type="fig"}), hospital-based studies (OR = 1.32, 95% CI: 1.20--1.46, *I*^2^ = 51.4%), high-quality studies (OR = 1.12, 95% CI: 1.06--1.18, *I*^2^ = 50.7%) and low quality studies (OR = 1.38, 95% CI: 1.17--1.62, *I*^2^ = 58.9%). Moreover, the *GSTM1* null genotype was also associated with an increased colon cancer risk (OR = 1.32, 95% CI: 1.16--1.51, *I*^2^ = 57.7%).

![Forest plot of the association between *GSTM1* present/null polymorphism and CRC risk in Caucasians](bsr-40-bsr20201927-g2){#F2}

![Forest plot of the association between *GSTM1* present/null polymorphism and CRC risk in Asians](bsr-40-bsr20201927-g3){#F3}

###### Odds ratios and 95% confidence intervals for the association between *GSTM1* present/null polymorphism and colorectal cancer

  Variable             No. of studies   No. of cases/controls   No. of *GSTM1* null cases/controls   Test of association   Test of heterogeneity                             
  -------------------- ---------------- ----------------------- ------------------------------------ --------------------- ----------------------- ------ --------- -------- ------
  Overall              86               24,931/36,537           13,180/18,518                        **1.17**              **1.10--1.23\***        5.24   \<0.001   192.37   55.8
  Ethnicity                                                                                                                                                                  
  Caucasian            44               13,363/17,720           7073/9042                            **1.14**              **1.05--1.23\***        3.22   0.001     99.37    56.7
  Asian                31               7561/12,426             4126/6384                            **1.19**              **1.08--1.32\***        3.39   0.001     63.44    52.7
  Source of controls                                                                                                                                                         
  HB                   51               7892/10,179             4168/4867                            **1.32**              **1.20--1.46\***        5.59   \<0.001   102.97   51.4
  PB                   35               17,039/26,358           9012/13,651                          1.03                  0.99--1.07              1.30   0.195     59.04    42.4
  Quality score                                                                                                                                                              
  ≥6                   55               21,644/32,009           11,484/16,403                        **1.11**              **1.05--1.18\***        3.84   \<0.001   109.44   50.7
  \<6                  31               3287/4528               1696/2115                            **1.38**              **1.17--1.62**          3.78   \<0.001   73.05    58.9
  Location                                                                                                                                                                   
  Colon cancer         23               5020/9672               2674/4728                            **1.32**              **1.16--1.51\***        4.13   \<0.001   51.95    57.7
  Rectal cancer        15               3696/9355               1787/4544                            0.99                  0.91--1.07              0.27   0.79      21.72    35.5
  Smoking                                                                                                                                                                    
  Smokers              16               3444/4007               1778/2027                            1.03                  0.94--1.13              0.56   0.572     20.26    26.0
  Non-smokers          15               2722/4177               1344/2083                            1.05                  0.87--1.25\*            0.56   0.578     37.26    62.4
  Gender                                                                                                                                                                     
  Males                9                3410/4132               1832/2226                            1.02                  0.93--1.11              0.32   0.748     12.07    33.7
  Females              9                2607/3905               1424/2198                            0.99                  0.85--1.17              0.08   0.932     15.14    47.2
  Site                                                                                                                                                                       
  Distal               10               1631/4017               880/2075                             1.26                  0.98--1.63\*            1.81   0.071     30.55    70.5
  Proximal             10               1246/4017               631/2075                             1.03                  0.78--1.36\*            0.21   0.832     24.41    63.1

### *GSTT1* present/null polymorphisms-- {#sec3-2-2}

[Table 5](#T5){ref-type="table"} lists the summary ORs and 95% CIs on the *GSTT1* null genotype with CRC risk. The included studies could not be merged together because *I*^2^ \> 75% was found between the *GSTT1* present/null polymorphism and CRC risk in the overall analysis and Caucasians. In subgroup analysis by ethnicity and quality score, a significantly increased CRC risk was observed in Asians (OR = 1.08, 95% CI: 1.02--1.15, *I*^2^ = 43.6%, [Figure 4](#F4){ref-type="fig"}) and low-quality studies (OR = 1.33, 95% CI: 1.16--1.53, *I*^2^ = 17.3%). The *GSTT1* null genotype was also associated with an increased rectal cancer risk (OR = 1.13, 95% CI: 1.01--1.27, *I*^2^ = 8.3%) in subgroup analysis by tumor location.

![Forest plot of the association between *GSTT1* present/null polymorphism and CRC risk in Asians](bsr-40-bsr20201927-g4){#F4}

###### Odds ratios and 95% confidence intervals for the association between *GSTT1* present/null polymorphism and colorectal cancer risk

  Variable             No. of studies   No. of cases/controls   No. of GSTT1 null cases/controls   Test of association   Test of heterogeneity                             
  -------------------- ---------------- ----------------------- ---------------------------------- --------------------- ----------------------- ------ --------- -------- ------
  Overall              64               19,725/28,725           6512/8888                          --                    --                      --     --        260.28   75.8
  Ethnicity                                                                                                                                                                
  Caucasian            34               11,337/14,632           2896/3205                          --                    --                      --     --        188.52   82.5
  Asian                23               6878/11,659             3286/5069                          **1.08**              **1.02--1.15**          2.49   0.013     39.03    43.6
  Source of controls                                                                                                                                                       
  HB                   36               6801/8894               2459/2552                          --                    --                      --     --        154.05   77.3
  PB                   28               12,924/19,831           4053/6336                          1.05                  0.95--1.16\*            0.96   0.337     90.02    70.0
  Quality score                                                                                                                                                            
  ≥6                   48               17,832/26,262           5903/8253                          --                    --                      --     --        234.52   80.0
  \<6                  16               1893/2463               609/635                            **1.33**              **1.16-1.53**           4.09   \<0.001   18.14    17.3
  Location                                                                                                                                                                 
  Colon cancer         11               2324/6062               679/1889                           1.11                  0.94-1.32               1.22   0.224     16.48    39.3
  Rectal cancer        10               2079/6661               695/2143                           **1.13**              **1.01-1.27**           2.09   0.036     9.81     8.3
  Smoking                                                                                                                                                                  
  Smokers              12               2037/2405               537/641                            1.04                  0.83--1.30              0.36   0.721     21.46    48.7
  Non-smokers          11               1730/2605               386/641                            0.96                  0.74--1.25              0.28   0.777     23.33    57.1
  Gender                                                                                                                                                                   
  Males                5                1930/2401               615/752                            1.13                  0.98--1.30              1.71   0.087     3.12     0.0
  Females              5                1467/2436               493/930                            1.10                  0.95--1.28              1.24   0.217     3.51     0.0
  Site                                                                                                                                                                     
  Distal               7                723/1677                194/368                            1.24                  0.91--1.69              1.34   0.179     10.99    45.4
  Proximal             7                340/1677                83/368                             1.04                  0.78--1.39              0.27   0.786     3.51     0.0

### Combined effects of *GSTM1* and *GSTT1* present/null polymorphisms {#sec3-2-3}

[Table 6](#T6){ref-type="table"} lists the summary ORs and 95% CIs on their combined effects with CRC risk. The *GSTM1* null/*GSTT1* null genotype was associated with an increased CRC risk in the overall analysis (− − vs. + +: OR = 1.42, 95% CI: 1.17--1.73, *I*^2^ = 68.6%; − − vs. + −: OR = 1.37, 95% CI: 1.00--1.88, *I*^2^ = 73.0%; − − vs. (+ −) + (− +): OR = 1.26, 95% CI: 1.05--1.51, *I*^2^ = 70.4%; − − vs. (+ −) + (− +) + (+ +): OR = 1.26, 95% CI: 1.09--1.46, *I*^2^ = 69.0%).

###### Combined genotype analysis of the GSTM1 and GSTT1 polymorphisms on risk of colorectal cancer

  Variables                      No. of studies   No. of cases/controls   Test of association   Test of heterogeneity                             
  ------------------------------ ---------------- ----------------------- --------------------- ----------------------- ------ --------- -------- -------
  − − vs. + +                                                                                                                                     
  Overall                        29               3543/5647               **1.42**              **1.17--1.73\***        3.50   \<0.001   89.24    68.6
  Ethnicity                                                                                                                                       
  Caucasian                      10               780/1371                --                    --                      --     --        52.35    82.8
  Asian                          14               2202/3255               **1.41**              **1.15--1.73\***        3.29   0.001     28.51    54.4
  Source of controls                                                                                                                              
  HB                             18               1193/1954               **1.53**              **1.28--1.83**          4.66   \<0.001   31.24    45.6
  PB                             11               2350/3337               --                    --                      --     --        51.81    80.7
  Quality score                                                                                                                                   
  ≥ 6                            21               3257/5144               **1.43**              **1.15--1.77**          3.19   0.001     75.95    73.7
  \< 6                           8                286/503                 1.38                  0.85**--**2.24\*        1.32   0.187     12.76    45.1
  − − vs. − +                                                                                                                                     
  Overall                        20               2469/3221               1.15                  0.92--1.44\*            1.21   0.226     46.25    58.9
  Ethnicity                                                                                                                                       
  Caucasian                      7                577/982                 0.89                  0.61--1.28\*            0.64   0.522     11.35    47.1
  Asian                          10               1604/1728               **1.28**              **1.11--1.48**          3.42   0.001     17.16    47.6
  Source of controls                                                                                                                              
  HB                             14               878/1392                1.21                  0.99--1.48              1.89   0.059     24.25    46.4
  PB                             6                1591/1829               --                    --                      --     --        20.28    75.3
  Quality score                                                                                                                                   
  ≥ 6                            13               2154/2727               1.20                  0.91--1.60\*            1.28   0.199     40.26    70.2
  \< 6                           7                315/494                 1.07                  0.77--1.47              0.39   0.693     5.99     0.0
  − − vs. + −                                                                                                                                     
  Overall                        20               1878/2218               **1.37**              **1.00--1.88\***        1.98   0.048     70.50    73.0
  Ethnicity                                                                                                                                       
  Caucasian                      7                314/474                 0.66                  0.37--1.17\*            1.42   0.154     18.89    68.2
  Asian                          10               1418/1426               --                    --                      --     --        36.61    75.4
  Source of controls                                                                                                                              
  HB                             14               582/790                 1.32                  0.83--2.09\*            1.18   0.239     44.80    71.0
  PB                             6                1296/1428               --                    --                      --     --        24.47    79.6
  Quality score                                                                                                                                   
  ≥ 6                            13               1646/1944               **1.60**              **1.15--2.22\***        2.82   0.005     39.67    69.7
  \< 6                           7                232/274                 --                    --                      --     --        28.60    79.0
  − − vs.(− +) + (+ −)                                                                                                                            
  Overall                        28               4842/7564               **1.26**              **1.05--1.51\***        2.45   0.014     91.18    70.4
  Ethnicity                                                                                                                                       
  Caucasian                      10               1203/1709               --                    --                      --     --        41.23    78.2
  Asian                          13               3070/4836               **1.50**              **1.20--1.86\***        3.60   \<0.001   40.06    70.0
  Source of controls                                                                                                                              
  HB                             17               1563/2293               1.23                  0.92--1.63\*            1.40   0.162     39.44    59.4
  PB                             11               3279/5271               --                    --                      --     --        50.60    80.2
  Quality score                                                                                                                                   
  ≥ 6                            20               4391/6934               **1.33**              **1.09--1.62\***        2.85   0.004     71.8     73.6
  \< 6                           8                451/630                 0.91                  0.53**--**1.54          0.36   0.715     18.80    62.8
  − − vs.(− +) + (+ −) + (+ +)                                                                                                                    
  Overall                        33               8270/14,381             **1.26**              **1.09--1.46\***        3.08   0.002     103.11   69.0
  Ethnicity                                                                                                                                       
  Caucasian                      8                1893/2888               --                    --                      --     --        47.52    79.0
  Asian                          17               5328/9617               **1.30**              **1.10--1.53\***        3.14   0.002     47.75    66.5
  Source of controls                                                                                                                              
  HB                             19               2620/3998               **1.38**              **1.19-1.60**           4.17   \<0.001   35.47    49.3
  PB                             14               5650/10,383             --                    --                      --     --        61.31    78.8
  Quality score                                                                                                                                   
  ≥ 6                            25               7647/13,393             **1.29**              **1.10--1.51\***        3.08   0.002     88.88    73.0
  \< 6                           8                623/988                 1.10                  0.72--1.70\*            0.45   0.656     14.27    0.047

\+ −: *GSTM1* present/GSTT1 null; − +: *GSTM1* null/*GSTT1* present; − −: *GSTM1* null/*GSTT1* null; + +: *GSTM1* present/*GSTT1* present; HB Hospital-based studies; PB Population-based studies

In subgroup analyses by ethnicity, source of controls, and quality score, the *GSTM1* null/*GSTT1* null genotype was associated with an increased CRC risk in Asians (− − vs. + +: OR = 1.41, 95% CI: 1.15--1.73, *I*^2^ = 54.4%, [Figure 5](#F5){ref-type="fig"}; − − vs. − +: OR = 1.28, 95% CI: 1.11--1.48, *I*^2^ = 47.6%; − − vs. (+ −) + (− +): OR = 1.50, 95% CI: 1.20--1.86, *I*^2^ = 70.0%; − − vs. (+ −) + (− +) + (+ +): OR = 1.38, 95% CI: 1.19--1.60, *I*^2^ = 49.3%), hospital-based studies (− − vs. + +: OR = 1.53, 95% CI: 1.28--1.83, *I*^2^ = 45.6%; − − vs. (+ −) + (− +) + (+ +): OR = 1.38, 95% CI: 1.19--1.60, *I*^2^ = 49.3%) and high-quality studies (− − vs. − +: OR = 1.43, 95% CI: 1.15--1.77, *I*^2^ = 73.7%; − − vs. + −: OR = 1.60, 95% CI: 1.16--2.22, *I*^2^ = 69.7%; − − vs. (+ −) + (− +): OR = 1.33, 95% CI: 1.09--1.62, *I*^2^ = 73.6%; − − vs. (+ −) + (− +) + (+ +): OR = 1.29, 95% CI: 1.10--1.51, *I*^2^ = 73.0%).

![Forest plot of the association between the combined of *GTSM1* present/null and *GSTT1* present/null polymorphisms and CRC risk in Asians](bsr-40-bsr20201927-g5){#F5}

### Heterogeneity and sensitivity analyses {#sec3-2-4}

Significant heterogeneity was detected in the meta-analysis, as shown in [Tables 4](#T4){ref-type="table"}--[6](#T6){ref-type="table"}. A meta-regression analysis revealed that sample size (*P*=0.002) was the source of heterogeneity for the *GSTM1* present/null polymorphism. Concerning the *GSTT1* present/null polymorphism and the combined effects of *GSTM1* and *GSTT1*, meta-regression analysis did not reveal a source of heterogeneity under any genetic model. Additionally, *I^2^* \> 75% as shown in [Tables 4](#T4){ref-type="table"}--[6](#T6){ref-type="table"}.

When the study of Laso et al. \[[@B82]\] was excluded, the values of heterogeneity dropped and the *GSTT1* null genotype was associated with an increased CRC risk in the following subgroups: Caucasians (OR = 1.24, 95% CI: 1.09--1.41, *I*^2^ = 70.8%) and hospital-based studies (OR = 1.19, 95% CI: 1.06--1.35, *I*^2^ = 54.5%). When the study of Martínez et al. \[[@B38]\] was excluded, the *I*^2^ value dropped and no significant association was found between the combined effects of *GSTM1* and *GSTT1* polymorphisms and CRC risk in Caucasians (− − vs. + +: OR = 1.22, 95% CI: 0.83--1.78, *I*^2^ = 55.6%; − − vs. (+ −) + (− +): OR = 0.81, 95% CI: 0.53--1.26, *I*^2^ = 68.1%; − − vs. (+ −) + (− +) + (+ +): OR = 0.99, 95% CI: 0.69--1.41, *I*^2^ = 57.0%) and population-based studies (− − vs. + +: OR = 1.11, 95% CI: 0.99--1.24, *I*^2^ = 28.9%; − − vs. (+ −) + (− +): OR = 1.16, 95% CI: 0.93--1.45, *I*^2^ = 73.9%; − − vs. (+ −) + (− +) + (+ +): OR = 1.08, 95% CI: 0.93--1.26, *I*^2^ = 63.5%). When the study of Gorukmez \[[@B49]\] was deleted, the *I*^2^ value dropped and no significant association was observed between the combined effects of *GSTM1* and *GSTT1* polymorphisms and CRC risk in low-quality studies (− − vs. + −: OR = 1.23, 95% CI: 0.58--2.59, *I*^2^ = 68.3%). When the study of Cong et al. \[[@B33]\] was excluded, the *I*^2^ value dropped and no significant association was observed between the combined effects of *GSTM1* present/null and *GSTT1* present/null polymorphisms and CRC risk in population-based studies (− − vs. + −: OR = 1.13, 95% CI: 0.78--1.65, *I*^2^ = 54.4%; − − vs. − +: OR = 0.88, 95% CI: 0.65--1.19, *I*^2^ = 55.3%). A single study was excluded each time to assess the stability of the results. [Figures 6](#F6){ref-type="fig"}--[12](#F12){ref-type="fig"} suggest that the results are stable in the present meta-analysis.

![Sensitive analysis of the null genotype of *GSTM1* on CRC risk in overall population](bsr-40-bsr20201927-g6){#F6}

![Sensitive analysis of the null genotype of *GSTT1* on CRC risk in overall population](bsr-40-bsr20201927-g7){#F7}

![Sensitive analysis of the combined effects of *GSTM1* and *GSTT1* on CRC risk in overall population (− − vs. + +)](bsr-40-bsr20201927-g8){#F8}

![Sensitive analysis of the combined effects of *GSTM1* and *GSTT1* on CRC risk in overall population (− − vs. + −)](bsr-40-bsr20201927-g9){#F9}

![Sensitive analysis of the combined effects of *GSTM1* and *GSTT1* on CRC risk in overall population (− − vs. − +)](bsr-40-bsr20201927-g10){#F10}

![Sensitive analysis of the combined effects of *GSTM1* and *GSTT1* on CRC risk in overall population (− − vs. (+ −) + (− +))](bsr-40-bsr20201927-g11){#F11}

![Sensitive analysis of the combined effects of *GSTM1* and *GSTT1* on CRC risk in overall population ((+ −) + (− +) + (+ +))](bsr-40-bsr20201927-g12){#F12}

### Publication bias {#sec3-2-5}

Begg\'s funnel plot and Egger\'s test were used to assess publication bias in the meta-analysis. The Begg\'s funnel plot shape and Egger's test (*P*\<0.001) revealed obvious publication bias between the *GSTM1* present/null polymorphism and CRC risk in the overall analysis. [Figure 13](#F13){ref-type="fig"} shows the Begg's funnel plots by the trim and fill method; 24 missing studies should be added to this. Notably, log OR and 95% CI did not alter significantly when the trim and fill method was used. No significant publication bias was observed for the *GSTT1* present/null polymorphism (*P*=0.195). Concerning their combined effects, no publication bias was detected under any genetic model (*P*=0.093 for − − vs. + +; *P*=0.398 for − − vs. + −; *P*=0.764 for − − vs. − +; *P*=0.643 for − − vs. (+ −) + (− +); *P*=0.280 for − − vs. (+ −) + (− +) + (+ +)).

![The Duval and Tweedie nonparametric "trim and fill" method's funnel plot of the *GSTM1* present/null polymorphism](bsr-40-bsr20201927-g13){#F13}

Discussion {#sec4}
==========

Strange et al. \[[@B106]\] in 1991 first reported an association between the *GSTM1* null genotype and colon adenocarcinoma risk. Chenevix-Trench et al. \[[@B21]\] first analyzed the association between the *GSTT1* null genotype and CRC risk in 1996. Deakin et al. \[[@B52]\] first examined their combined effects with CRC risk in 1996. Since then, many case-control studies have investigated the associations but the results are still inconsistent. Hence, an updated meta-analysis was performed to explore the *GSTM1* null genotype, *GSTT1* null genotype, and their combined effects with CRC risk.

Overall, this meta-analysis indicates that the *GSTM1* and *GSTT1* null genotypes are associated with increased CRC risk in Asians and Caucasians, and the *GSTM1* null/*GSTT1* null genotype was associated with increased CRC risk in Asians, but not in Africans and Indians. In addition, the *GSTM1* null genotype was associated with colon cancer risk but not rectal cancer, while conversely that the *GSTT1* null genotype was associated with rectal caner but not colon cancer.

Actually, it may not be uncommon that the same polymorphism played different roles in cancer risk among different ethnic population, because cancer is a complicated multi-genetic disease, and different genetic backgrounds may contribute to the discrepancy \[[@B134]\]. In addition, the differences might arise by chance because studies in Indians and Africans with small sample size may have insufficient statistical power to generate an authoritative risk estimate \[[@B135]\]. Therefore, a large population-based case-control study is required to confirm the GSTM1, GSTT1 and their combined effects with CRC risk in Indians and Africans. Nine \[[@B32],[@B33],[@B46],[@B59],[@B90],[@B93],[@B99],[@B101],[@B105]\] and seven \[[@B38],[@B45],[@B48],[@B75],[@B81],[@B83],[@B85]\] studies indicated that the *GSTM1* null genotype was associated with an increased CRC risk in Asians and Caucasians, respectively. Five \[[@B33],[@B47],[@B78],[@B93],[@B102]\] and eight \[[@B26],[@B38],[@B49],[@B52],[@B62],[@B80],[@B82],[@B89]\] studies indicated that the *GSTT1* null genotype had a significantly increased CRC risk in Asians and Caucasians, respectively. Moreover, five studies \[[@B33],[@B41],[@B57],[@B90],[@B99]\] reported a significant association between their combined effects and CRC risk in Asians. The results of present study strongly supported these findings.

Subgroup analysis by source of control found a significant association in hospital-based studies, but not in population-based studies in the present meta-analysis. However, hospital-based controls are not likely to replace the general population because they may have more bias than population-based studies \[[@B136]\]. Therefore, the results of hospital-based controls should be carefully explained. Heterogeneity is a common problem in meta-analyses. The present study observed several high levels of heterogeneity (*I^2^* \> 75%), and the results of meta-regression analysis indicated that sample size was the source of heterogeneity between the *GSTM1* null genotype and CRC risk. Small sample size studies may be important confounding bias in molecular epidemiological studies, because random error and bias were common in the studies with small sample sizes, and the results were unreliable \[[@B137]\]. Furthermore, small sample studies were easier to accept if there was a positive report as they tend to yield false-positive results because they may be not rigorous and are often of low-quality. In addition, several value of *I^2^* \> 75% dropped when a single study was excluded, the results indicate that source of heterogeneity also may be from one or multiple small sample or low quality studies. [Figure 13](#F13){ref-type="fig"} indicates that the asymmetry of the funnel plot was caused by studies with low-quality small samples.

A total of 13 meta-analyses \[[@B115],[@B126],[@B127]\] were conducted between 2010 and 2019 reported on the associations between the *GSTM1* present/null and/or *GSTT1* present/null polymorphisms with CRC risk. Cai et al. \[[@B115]\] examined 17 studies that included 5907 CRC cases and 9726 controls to explore the association between the *GSTM1* null genotype and CRC risk in Asians, reporting that the *GSTM1* null genotype was associated with an increased CRC risk. Liao et al. \[[@B116]\] examined 23 studies including 5058 cases and 5999 controls to show that the *GSTT1* null genotype was associated with an increased CRC risk in Caucasians and Asians. Wan et al. \[[@B117]\] identified 30 studies of 7635 cases and 12,911 controls in all races, and demonstrated that the *GSTT1* null genotype was associated with an increased CRC risk in Caucasians. Teng et al. \[[@B118]\] examined 13 studies (including 2225 cases and 3990 controls) to assess the *GSTM1* null genotype with CRC risk and they found that the *GSTM1* null genotype was associated with an increased CRC risk in Chinese. Gao et al. \[[@B119]\] assessed the association of the *GSTM1* null genotype with CRC risk in all races (including 10,009 cases and 15,070 controls from 36 studies) and indicated that the *GSTM1* null genotype was associated with an increased risk of CRC, especially in Caucasians. Qin et al. \[[@B120]\] selected 46 studies including 15,373 cases and 21,238 controls to show that the *GSTT1* null genotype may contribute to an increased CRC risk in Asians and Caucasians. Wang et al. \[[@B121]\] (19 studies including 3130 cases and 6423 controls) found that the null genotypes of *GSTM1* and *GSTT1* and the dual null genotype of *GSTM1/GSTT1* were not associated with CRC risk in Chinese population. The examination of 44 studies of *GSTM1* (11,998 CRC cases and 17,552 controls) and 34 studies of *GSTT1* (8596 CRC cases and 13,589 controls) by Economopoulos and Sergentanis \[[@B122]\] indicated that the *GSTM1* and *GSTT1* null genotypes were associated with an increased CRC risk in Caucasians. Li et al. \[[@B123]\] analyzed 33 studies (including 8502 CRC Asian cases and 13,699 controls) and indicated that the *GSTM1* null genotype conferred susceptibility to CRC, especially in Chinese population. Xu et al. \[[@B124]\] examined 13 publications of 4832 cases and 7045 controls, demonstrating that the *GSTT1* null genotype was associated with an increased CRC risk in Asians. Zhong et al. \[[@B125]\] conducted an association of 12 studies involving 4517 cases and 6607 controls, and suggested that the *GSTT1* null genotype contributed to an increased CRC risk in Asians. Du et al. \[[@B126]\] examined 12 studies of *GSTM1* and 8 studies of *GSTT1*, and found no association on the *GSTM1* or *GSTT1* null genotype with CRC risk. Huang et al. \[[@B127]\] selected 55 studies including 17,498 cases and 26,441 controls to show that the *GSTM1* null genotype was a risk factor for CRC.

The current meta-analysis has several advantages over previous meta-analyses \[[@B115],[@B126],[@B127]\]. First, the sample size was much larger, with 86 case--control studies including 24,931 CRC cases and 36,537 controls evaluated for the *GSTM1* present/null polymorphism, 64 case--control studies including 19,725 CRC cases and 28,725 controls for the *GSTT1* present/null polymorphism, and 33 case-control studies including 8306 CRC cases and 14,369 controls for their combined effects in all races. Second, this is the first meta-analysis to explore their combined effects in overall population. Third, we used a meta-regression analysis method to explore the source of heterogeneity. Finally, the current meta-analysis included the most recent relevant publications to produce more accurate results.

Similar to previous meta-analyses, our study also has several limitations. First, only published articles were selected. Hence, publication bias may be found as shown in [Figure 13](#F13){ref-type="fig"}. Moreover, positive results are known to be published more readily than negative ones. If negative results were included, an underestimation of the effect may be observed. Second, some case--control studies were based on hospital-based controls. These controls with non-cancerous disease may influence the pooled results in this study. Therefore, the use of population-based control studies may be more appropriate than hospital-based control studies. Third, only one study on Africans and Indians were included in the present study. Further new original studies were need on these issues in Africans and Indians.

In summary, the present study indicates that the *GSTM1* null genotype is associated with increased CRC risk in Asians and Caucasians, the *GSTT1* null genotype is associated with increased CRC risk in Asians, and the *GSTM1* null/*GSTT1* null genotype was associated with increased CRC risk in Asians. Further investigations involving large population-based studies should be conducted to explore the associations on the *GSTM1* null genotype, *GSTT1* null genotype and their combined effects with CRC risk.
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